Zai Lab (NASDAQ:ZLAB) Stock: Insider Richard Gaynor Acquires 1,228 Shares

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director Richard Gaynor purchased 1,228 shares of Zai Lab stock in a transaction on Tuesday, November 10th. The stock was bought at an average cost of $27.19 per share, with a total value of $33,389.32. Following the transaction, the director directly owned 81,965 shares of the company’s stock, valued at approximately $2,228,628.35. The trade was a 1.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Zai Lab Stock Performance

Shares of ZLAB traded down $1.44 during trading hours on Friday, hitting $24.60. 1,224,327 shares of the company were exchanged, compared to its average volume of 1,295,968. The company has a market cap of $3.08 billion, a PE ratio of -13.74 and a beta of 0.77. The firm’s 50 day moving average is $24.62 and its 200-day moving average is $21.26. Zai Lab Limited Unsponsored ADR has a 52 week low of $15.96 and a 52 week high of $29.02.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. The business had revenue of $108.21 million for the quarter, compared to analyst estimates of $107.90 million. As a group, equities analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.19 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZLAB has been the topic of a number of recent analyst reports. Citigroup lifted their price target on shares of Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a report on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zai Lab has an average rating of “Moderate Buy” and an average target price of $37.25.

Recent Zai Lab Headlines

These are some of the ZLAB headlines that stood out recently:

• Positive Sentiment: Five Zai Lab medicines were included in China’s 2026 National Reimbursement Drug List: KarXT and VYVGART Hytrulo® for the first time, plus three renewals covering oncology and infectious-disease treatments. Broader reimbursement could improve patient access and support commercial growth, though the reports do not specify the financial impact or reimbursement pricing. Article: Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo in China’s 2026 National Reimbursement Drug List
• Positive Sentiment: Zai Lab reported positive first-in-human results for ZL-1503, its investigational bispecific antibody for atopic dermatitis, with rapid and sustained inhibition of key biomarkers. The data support further development and potential quarterly maintenance dosing, but the candidate remains early in clinical testing. Article: Zai Lab Presents Positive First-in-Human Data for ZL-1503
• Positive Sentiment: Director Richard Gaynor bought 1,228 shares at an average $27.19, increasing his position by 1.52%. The purchase may be viewed as a modest confidence signal. SEC filing: Director share purchase

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC grew its position in Zai Lab by 65.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock worth $8,692,000 after purchasing an additional 130,000 shares during the last quarter. HighVista Strategies LLC bought a new position in shares of Zai Lab during the 3rd quarter worth about $609,000. Nan Fung Trinity HK Ltd. increased its holdings in shares of Zai Lab by 106.9% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after purchasing an additional 151,883 shares during the period. Alps Advisors Inc. raised its position in shares of Zai Lab by 34.9% during the third quarter. Alps Advisors Inc. now owns 148,993 shares of the company’s stock valued at $3,924,000 after buying an additional 38,562 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Zai Lab during the third quarter valued at about $62,000. 41.65% of the stock is currently owned by institutional investors.

About Zai Lab

Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.